Bern researcher viewing sample)

Research & Development

Innovation is in Our DNA

Innovation is in our DNA and is the core of everything we do at CSL Behring. Our team of over 1,700 R&D experts are dedicated to developing and delivering new therapies to solve unmet medical needs and save lives. We have created one of the largest and most efficient plasma collection networks in the world and strive to be the best at delivering safe and effective medicines for our patients.

  • US $702.4 million

    was invested in R&D in 2017/18

  • US $2.9 billion

    in R&D investments in the last 5 years

  • >1,700

    research & development employees

Female Scientist at Broadmeadows

Investment in our R&D

Investment in R&D is an important driver for CSL Behring’s future growth. We have a high quality and potentially valuable portfolio of projects in various stages of development. We continue to make a balanced investment in the life cycle management and market development of existing products that bring short to mid-term commercial benefits, and we make strategic investments in longer term, higher risk and high opportunity new product development activities.

Current Clinical Trials

Therapeutic Area Condition Description
Bleeding Disorders
Hemophilia A An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A. Learn More
Hemophilia B A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B Learn More
Hemophilia A & B A Study to Investigate the Pharmacokinetics, Efficacy, and Safety of rVIIa-FP (CSL 689) in Subjects With Hemophilia (A or B) and Inhibitors Learn More
Congenital Fibrinogen Deficiency An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency Completed
Von Willebrand Study of Voncento® in Subjects With Von Willebrand Disease Completed
Warfarin Reversal An Observational Study of the Risk of Thromboembolic Events Among Adult Patients Treated With KCENTRA® Compared With Plasma for Urgent Reversal of Vitamin K Antagonist Therapy in the Setting of Acute Major Bleeding Learn More
Cardiovascular Acute Coronary Syndrome  Study to investigate CSL112 in Subjects With Acute Coronary Syndrome Learn More
  Coronary Heart Disease Assessing the pharmacokinetics, safety, and tolerability of CSL112 in healthy Japanese and Caucasian adults Learn More
Immunoglobulins Chronic Inflammatory Demyelinating Polyneuropathy Extension Study of Maintenance Treatment with Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Learn More
  Hereditary Angioedema (HAE) A Multicenter, Randomized, Placebo-controlled, Parallel-arm Study to Investigate the Efficacy, Pharmacokinetics, and Safety of CSL312 in Subjects With Hereditary Angioedema Learn More 
  Pediatric CIDP Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP Learn More 
  Primary Immune Deficiency (PID) Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID) Learn More
Primary Immune Deficiency (PID) Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules Completed
  Primary Immune Deficiency (PID) Comparison of 2 Infusion Devices With Respect to Pharmacokinetics, Safety, and Tolerability of Hizentra: An Investigational Wearable Infusor and the Crono S-PID-50 Infusion Pump  Learn More
Therapeutic Proteins Other Inflammatory or immune system disorders Dose escalation, placebo-controlled phase 1 study to assess the safety and tolerability of CSL324 in healthy adults Learn More
Transplant Antibody-mediated kidney transplant rejection Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection in Adult Renal Transplant Recipients Learn More

World-Class R&D Network

CSL is a global specialty biotech with a strong commitment to funding research and development of medicines to support its continued growth. We operate as one integrated global research and development organization that assembles coordinated global project teams, drawing together staff from different countries depending on their expertise. Our teams rely on a project management framework that facilitates collaboration across national and cultural boundaries.

CSL Parkville office

CSL Limited
Global Corporate HQ
R&D and Manufacturing

CSL Behring
R&D and Manufacturing

Bio21 Global Research and Translational Medicine Hub

Marburg employees

CSL Behring
R&D and Manufacturing

Kankakee office
United States

CSL Behring
Head Office and R&D

CSL Behring
R&D and Manufacturing


Bern, Switzerland

CSL Behring
R&D and Manufacturing

Researchers taking notes

CSL Behring

Asian male and caucasian female in a lab

R&D and Manufacturing

R&D Briefings Archives

R&D Briefing December 2017 pdf
R&D Briefing December 2016 pdf
R&D Briefing December 2015 pdf
R&D Briefing December 2014 pdf
Product Pipeline

Innovation is in our DNA; Learn more about what's in our pipeline.

Learn More
Clinical Trials

Find out how to participate.

Learn More
Job Opportunities

Join us and make history with the brightest, most passionate people from every discipline.

Learn More

Get our latest Vita stories in your inbox
First name
Last name


You have now been added
to the CSL Behring Vita list